儿童肾病患者的霉酚酸与他克莫司模型引导精准给药结构化评估
该研究在肾病患儿中评估霉酚酸和他克莫司的模型引导精准给药,采用群体药代动力学模型选择、真实世界数据回顾性评价、有限采样策略评估及前瞻性预测性能验证。结果显示3点采样可准确估计当前AUC0-12,但两药在下次 occasion 的AUC预测误差均较大,提示需重复治疗药物监测。
要点
- 3点采样(0、1、2 h)可准确估计霉酚酸和他克莫司当前AUC0-12。
- 两药下次 occasion 的AUC预测误差大,长期预测不可靠。
- 建议对两药进行重复治疗药物监测以指导剂量调整。
核心结论
- 模型引导精准给药引导的有限采样策略可用于估计霉酚酸和他克莫司的当前暴露,两药可采用相似采样时间。
- 准确长期预测不可能,强调需要重复治疗药物监测。
研究设计与样本
- 研究步骤包括:群体药代动力学模型选择;真实世界数据回顾性评价;有限采样策略评估;前瞻性评估预测下次 occasion(3个月后)AUC0-12的性能。
- 可接受的偏倚和不精密度定义为平均预测误差和归一化均方根误差小于25%。
主要发现
- 霉酚酸3点采样(0、1、2 h)估计AUC0-12的平均预测误差为0.1%(-0.3至0.6%),归一化均方根误差为21.0%(7.1-34.8%)。
- 他克莫司3点采样(0、1、2 h)估计AUC0-12的平均预测误差为0.2%(0.03-0.4%),归一化均方根误差为7.8%(3.0-12.6%)。
- 霉酚酸预测下次 occasion AUC0-12的平均预测误差为15.4%(14.4-16.4%),归一化均方根误差为48.6%(18.2-79.0%)。
- 他克莫司预测下次 occasion AUC0-12的平均预测误差为64.2%(59.7-68.7%),归一化均方根误差为210%(37.1-383%)。
- occasion 间变异大限制了对未来AUC0-12的预测。
临床怎么用
- 临床可采用0、1、2 h三点采样结合模型引导精准给药估计霉酚酸和他克莫司的当前AUC0-12。
- 不应依赖单次模型预测长期AUC,需定期重复治疗药物监测以调整剂量。
局限性
- occasion 间变异大导致长期预测性能差。
- 研究纳入儿童肾病患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Mycophenolic acid and tacrolimus are frequently used in kidney transplant recipients and patients with nephrotic syndrome. For both drugs, therapeutic drug monitoring is recommended. Model-informed precision dosing, not only uses population pharmacokinetic data but also increases flexibility. To optimize treatment with mycophenolic acid and tacrolimus using a limited number of samples, we evaluated model-informed precision dosing for both drugs. METHODS: We performed the following steps: (1) selection of population pharmacokinetic models; (2) retrospective evaluation using real-world data; and (3) evaluation of limited sampling strategies, (4) prospective evaluation of the predictive performance by predicting an area under the concentration-time curve from time zero to 12 h at a next occasion (3 months later). Acceptable bias and imprecision were defined as a mean prediction error and a normalized root mean square error of less than 25%. RESULTS: A 3‑point sampling schedule (t = 0, t = 1, t = 2 h) provided accurate area under the concentration-time curve from time zero to 12 h estimation for both drugs, with mean prediction error and normalized root mean square error of 0.1% (- 0.3 to 0.6%) and 21.0% (7.1-34.8%) for mycophenolic acid, and 0.2% (0.03-0.4%) and 7.8% (3.0-12.6%) for tacrolimus. Substantial between-occasion variability limited the prediction of future area under the concentration-time curve from time zero to 12 h. For mycophenolic acid, the mean prediction error was 15.4% (14.4-16.4%) and the normalized root mean square error was 48.6% (18.2-79.0%). For tacrolimus, corresponding values were 64.2% (59.7-68.7%) for mean prediction error and 210% (37.1-383%) for normalized root mean square error. CONCLUSIONS: Model-informed precision dosing-guided limited sampling strategies are feasible for estimation of current exposure using similar sampling times for mycophenolic acid and tacrolimus. Accurate long-term prediction is not possible, underscoring the need for repeated therapeutic drug monitoring. CLINICAL TRIAL REGISTRATION: NCT06095895.
引用
- Heida A, Cornelissen EAM, Aarnoutse RE, et al. Structured Evaluation of Model-Informed Precision Dosing of Mycophenolic Acid and Tacrolimus in Pediatric Patients with Kidney Disease. Clin Pharmacokinet. 2026. PMID: 42814375. doi:10.1007/s40262-026-01708-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。